Cargando…

Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?

Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehlers, Anna M., den Hartog Jager, Constance F., Kardol-Hoefnagel, Tineke, Katsburg, Miriam M.D., Knulst, André C., Otten, Henny G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130674/
https://www.ncbi.nlm.nih.gov/pubmed/34017336
http://dx.doi.org/10.3389/fimmu.2021.660037
_version_ 1783694568928051200
author Ehlers, Anna M.
den Hartog Jager, Constance F.
Kardol-Hoefnagel, Tineke
Katsburg, Miriam M.D.
Knulst, André C.
Otten, Henny G.
author_facet Ehlers, Anna M.
den Hartog Jager, Constance F.
Kardol-Hoefnagel, Tineke
Katsburg, Miriam M.D.
Knulst, André C.
Otten, Henny G.
author_sort Ehlers, Anna M.
collection PubMed
description Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strategies to generate human mAbs from peripheral blood have been described and used in several studies including single cell sequencing of antigen-binding B cells and the establishment of antigen-specific monoclonal Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines (LCLs). However, direct comparisons of these two strategies are scarce. Hence, we sought to set up these two strategies in our laboratory using peanut 2S albumins (allergens) and the autoantigen anti-Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2, alternatively ‘ARHGDIB’) as antigen targets to directly compare these strategies regarding costs, time expenditure, recovery, throughput and complexity. Regarding single cell sequencing, up to 50% of corresponding V(D)J gene transcripts were successfully amplified of which 54% were successfully cloned into expression vectors used for heterologous expression. Seventy-five percent of heterologously expressed mAbs showed specific binding to peanut 2S albumins resulting in an overall recovery of 20.3%, which may be increased to around 29% by ordering gene sequences commercially for antibody cloning. In comparison, the establishment of monoclonal EBV-LCLs showed a lower overall recovery of around 17.6%. Heterologous expression of a mAb carrying the same variable region as its native counterpart showed comparable concentration-dependent binding abilities. By directly comparing those two strategies, single cell sequencing allows a broad examination of antigen-binding mAbs in a moderate-throughput manner, while the establishment of monoclonal EBV-LCLs is a powerful tool to select a small number of highly reactive mAbs restricted to certain B cell subpopulations. Overall, both strategies, initially set-up for peanut 2S albumins, are suitable to obtain human mAbs and they are easily transferrable to other target antigens as shown for ARHGDIB.
format Online
Article
Text
id pubmed-8130674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81306742021-05-19 Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? Ehlers, Anna M. den Hartog Jager, Constance F. Kardol-Hoefnagel, Tineke Katsburg, Miriam M.D. Knulst, André C. Otten, Henny G. Front Immunol Immunology Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strategies to generate human mAbs from peripheral blood have been described and used in several studies including single cell sequencing of antigen-binding B cells and the establishment of antigen-specific monoclonal Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines (LCLs). However, direct comparisons of these two strategies are scarce. Hence, we sought to set up these two strategies in our laboratory using peanut 2S albumins (allergens) and the autoantigen anti-Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2, alternatively ‘ARHGDIB’) as antigen targets to directly compare these strategies regarding costs, time expenditure, recovery, throughput and complexity. Regarding single cell sequencing, up to 50% of corresponding V(D)J gene transcripts were successfully amplified of which 54% were successfully cloned into expression vectors used for heterologous expression. Seventy-five percent of heterologously expressed mAbs showed specific binding to peanut 2S albumins resulting in an overall recovery of 20.3%, which may be increased to around 29% by ordering gene sequences commercially for antibody cloning. In comparison, the establishment of monoclonal EBV-LCLs showed a lower overall recovery of around 17.6%. Heterologous expression of a mAb carrying the same variable region as its native counterpart showed comparable concentration-dependent binding abilities. By directly comparing those two strategies, single cell sequencing allows a broad examination of antigen-binding mAbs in a moderate-throughput manner, while the establishment of monoclonal EBV-LCLs is a powerful tool to select a small number of highly reactive mAbs restricted to certain B cell subpopulations. Overall, both strategies, initially set-up for peanut 2S albumins, are suitable to obtain human mAbs and they are easily transferrable to other target antigens as shown for ARHGDIB. Frontiers Media S.A. 2021-05-04 /pmc/articles/PMC8130674/ /pubmed/34017336 http://dx.doi.org/10.3389/fimmu.2021.660037 Text en Copyright © 2021 Ehlers, den Hartog Jager, Kardol-Hoefnagel, Katsburg, Knulst and Otten https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ehlers, Anna M.
den Hartog Jager, Constance F.
Kardol-Hoefnagel, Tineke
Katsburg, Miriam M.D.
Knulst, André C.
Otten, Henny G.
Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title_full Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title_fullStr Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title_full_unstemmed Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title_short Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?
title_sort comparison of two strategies to generate antigen-specific human monoclonal antibodies: which method to choose for which purpose?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130674/
https://www.ncbi.nlm.nih.gov/pubmed/34017336
http://dx.doi.org/10.3389/fimmu.2021.660037
work_keys_str_mv AT ehlersannam comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose
AT denhartogjagerconstancef comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose
AT kardolhoefnageltineke comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose
AT katsburgmiriammd comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose
AT knulstandrec comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose
AT ottenhennyg comparisonoftwostrategiestogenerateantigenspecifichumanmonoclonalantibodieswhichmethodtochooseforwhichpurpose